[one_half]

The LASER Trial

The trial is assessing whether a new treatment device might help to reduce the frequency of severe asthma attacks in patients with allergic asthma.

Asthma affects over 5 million people in the UK. Half a million of these have a severe form of the condition. Potentially life threatening attacks, known as exacerbations, are a frequent occurrence. Current treatment options to reduce the frequency of these exacerbations are limited.

The LASER trial will evaluate the effectiveness of a new treatment – Temperature Controlled Laminar Airflow (TLA.) TLA is delivered by an Airsonett® machine. The machine is used overnight in the patient’s home at the bedside. The machine filters allergy particles from the air overnight, allowing patients to sleep and ‘rest’ their lungs.

[/one_half] [one_half_last]
lady-resting
[/one_half_last]
[content_block bg_image=”” max_bg_width=”yes” bg_fixed=”no” bg_position=”center bottom” bg_repeat=”repeat-x” parallax_scroll=”no” bg_color=”#293037″ content_padding=”30px 0 0″ font_color=”#FFFFFF” class=”we-are-passionate-block”]

Could you help test a new treatment for severe Asthma?

The TLA device has been shown to be safe for patients and effective in reducing symptoms of asthma. We now need to explore in a larger trial whether the treatment can reduce asthma attacks and asthma symptoms, such as coughing and wheezing. We will assess whether using the machine in the NHS would be cost-effective and acceptable for patients.

Study involves 222 adults

We will include 222 adults, half of whom will be given a TLA device that is working, and the other half will be given a device which has been inactivated (the filtering process will be switched off, although the participants will not be able to tell that this has occurred).

12 month study

All patients will continue receiving their usual treatments. Participants will be in the study for 12 months, and will report their asthma attacks to the trial team whenever they occur during this period. In addition, they will visit the trial team 4 times (after 3, 6, 9 and 12 months) to assess their asthma control and quality of life.

[custom_button text=”Register your Interest” title=”Register your Interest” url=”#features-toc-title” size=”large” bg_color=”#FD7800″ text_color=”#FFFFFF” align=”left”]
mobile-tablet
[/content_block]
[one_half] 3-circles-tla
[/one_half] [one_half_last]

TLA device

The machine is known as a ‘Temperature-controlled Laminar Airflow (TLA)’ device, and remains at the patient’s bedside and is switched on every night, requiring no masks or other uncomfortable equipment, and is very safe and easy to use.

The device works by filtering out the allergy particles in the air of the patient’s breathing zone, allowing the patient’s lungs and airways to ‘rest’ in clean air overnight.

[/one_half_last]
[divider]
[one_half]

Do you suffer with severe Asthma?

The LASER Trial is a clinical trial for patients with allergic asthma. The trial has been designed to determine whether TLA treatment is effective in reducing the number of asthma attacks suffered by patients and to see if the treatment can improve patient’s asthma control and quality of life.

The Trial will include 222 adults, half of whom will be given a TLA device that is working, and the other half will be given a device which has been inactivated (the filtering process will be switched off, although the participants will not be able to tell that this has occurred). Which participant receives the working or deactivated device will be decided by a random process and will be unknown to the researcher and the participant.

[/one_half] [one_half_last]
patient-with-inhaler
[/one_half_last]
[divider]
[one_half]
group-doctors
[/one_half] [one_half_last]

Do you treat Patients with severe Asthma?

Temperature-controlled Laminar Airflow (TLA) is an evidence-based, non-pharmaceutical treatment for atopic asthma. The treatment is non-invasive and has an excellent safety record. TLA treatment works by stopping body convection and creating an area of essentially allergen free air in the patient’s breathing zone overnight.

TLA treatment drastically reduces the level of allergens inhaled during night-time sleep and gives the asthmatic patient’s hyperactive immune system long and regular periods of essential recovery. TLA treatment is delivered by a device called an Airsonett® device.

[/one_half_last]

The LASER Trial - A breath of fresh air in Asthma!

The LASER Trial is funded by the National Institute for Health Research Health Technology Assessment Programme
(Project number 12/33/28)

[clear]
Information on the LASER Trial March 12, 2015